Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients-A case-control study

2014 ◽  
Vol 110 (6) ◽  
pp. 661-665 ◽  
Author(s):  
Tamar Safra ◽  
Dan Grisaru ◽  
Moshe Inbar ◽  
Subhi Abu-Abeid ◽  
Danit Dayan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Case Control Study ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Case Control ◽  
Free Survival ◽  
Control Study

Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study

2014 ◽  
Vol 21 (11) ◽  
pp. 3621-3627 ◽  
Author(s):  
Jean-François Le Brun ◽  
Loic Campion ◽  
Dominique Berton-Rigaud ◽  
Gérard Lorimier ◽  
Frédéric Marchal ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Survival Benefit ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Case Control Study ◽  
Recurrent Ovarian Cancer ◽  
Case Control ◽  
Control Study

Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: A 3-year experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17094-e17094
Author(s):  
Alberto Mendivil ◽  
Lisa Nicole Abaid ◽  
John V. Brown ◽  
Kristina Mori ◽  
Katrina Lopez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Disease Progression ◽  
Cancer Patients ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Progression Free Survival ◽  
Advanced Stage ◽  
Free Survival ◽  
Primary Induction

e17094 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) potentially confers significant survival benefits in the management of ovarian cancer although the long-term data remain scant. We sought to compare the survival rates of advanced stage ovarian cancer patients who were treated with primary induction therapy alone or in conjunction with consolidation HIPEC. Methods: Sixty-nine ovarian cancer patients who underwent surgery and completed their primary induction chemotherapy were treated with consolidation carboplatin (AUC 10) based HIPEC and compared to a historical cohort that received surgery and primary chemotherapy alone (n=69). The demographic and clinical characteristics in which we were primarily interested included: patient age, body mass index, surgery and pathology data, chemotherapy regimen, toxicity, and progression free/overall survival. Results: The two patient groups were similar in terms of tumor characteristics, cyto-reductive status, distribution of neoadjuvant chemotherapy and number of maintenance chemotherapy cycles administered (P> 0.05). Progression free survival was significantly more pronounced in the HIPEC (25.1 months) patients compared to the control group (20 months) (P=0.024) and there was a decreased risk of disease progression accorded to the patients treated with HIPEC (HR, 2.1028; 95% CI: 1.2941 to 3.4167; P=0.0027). However, we did not discern any HIPEC related overall survival advantages (P=0.29). Conclusions: The results from our ovarian cancer study suggest that adjunctive HIPEC proffers a significant progression free survival advantage and a decreased risk for disease progression. There was, however, no overall survival advantage discerned in the HIPEC group. We also recognize that HIPEC remains controversial and thus, randomized studies evaluating HIPEC compared to standard chemotherapy in the management of ovarian cancer are warranted.

scholarly journals Intraperitoneal chemotherapy in pretreated ovarian cancer patients: a retrospective case-control study

2015 ◽  
Vol 26 ◽  
pp. vi35
Author(s):  
A. Casarin ◽  
M.O. Nicoletto ◽  
S. Valpione ◽  
A. Baldoni ◽  
Z. Baretta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Intraperitoneal Chemotherapy ◽  
Case Control Study ◽  
Case Control ◽  
Retrospective Case ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document